Corxel to Go Public Amid Advancements in Oral GLP-1 Agonists | Retatrutide News

Corxel is going public as it moves its oral GLP-1 agonist into Phase 3 trials. This reflects the competitive landscape in GLP-1 drug development, includ...
Market News · October 27, 2026